drugset / Trial / NCT07525141
A Study of JNJ-1761981 in Participants With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
Timeline
- Start
- 2026-05-18
- Primary completion
- 2028-01-12
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-1761981 | Unknown | — | Other |
| Background | Cetrelimab | Monoclonal antibody | — | Intravenous |